Treg, an immunosuppressive subset of CD4+ T cells, is a potential therapeutic approach to autoimmune diseases, such as systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease (Raffin et al., 2020). The gene discussed is CD4; the disease is systemic lupus erythematosus.